HUTCHMED (China) Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
HCM Nasdaq 2830 www.hutch-med.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for HUTCHMED (China) Limited

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - Jan 13th, 2026 9:00 pm
Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know - Jan 7th, 2026 7:55 am
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - Jan 6th, 2026 5:00 pm
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma - Jan 4th, 2026 5:00 pm
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification - Dec 30th, 2025 3:00 am
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma - Dec 29th, 2025 1:35 am
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors - Dec 16th, 2025 5:00 pm
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China - Dec 7th, 2025 5:00 pm
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - Nov 26th, 2025 5:00 pm
Private equity firms among HUTCHMED (China) Limited's (LON:HCM) largest stockholders and were hit after last week's 4.8% price drop - Nov 23rd, 2025 12:15 am
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Nov 5th, 2025 6:35 am
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO® - Nov 4th, 2025 5:00 pm
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event - Nov 2nd, 2025 5:00 pm
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - Oct 31st, 2025 6:35 am
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - Oct 30th, 2025 6:00 pm
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 22nd, 2025 6:00 pm
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - Oct 14th, 2025 2:30 am
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - Oct 12th, 2025 10:00 pm
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 - Oct 1st, 2025 6:00 pm
HUTCHMED (China) (LON:HCM) shareholder returns have been respectable, earning 63% in 3 years - Sep 19th, 2025 12:01 am